Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunophenotyping in Metastatic Renal Cell Carcinoma Patients Receiving Ablative Therapy

NCT05112627 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT05112627
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05112627 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunophenotyping in Metastatic Renal Cell Carcinoma Patients Receiving Ablative Therapy
Lead sponsor
Mayo Clinic
Phase
Observational
Overall status
Completed
Start date
January 24, 2022
Completion date
May 15, 2024
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic renal cell carcinoma, stage iv renal cell cancer ajcc v8